Maternal TDF and FTC to Reduce NNRTI Resistance Mutations After Intrapartum NVP
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the addition of tenofovir (TDF) and
emtricitabine (FTC)to a standard PMTCT regimen containing single-dose nevirapine (NVP) can
reduce the development of post-ingestion HIV resistance to non-nucleoside reverse
transcriptase inhibitors (NNRTIs).